文献速递腹部MR

肝细胞癌患者钆塞酸增强MRI肝胆期:切除、消融或TACE前的预后特征

Hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with HCC: prognostic features before resection, ablation, or TACE.
PubMed 文献 · Eur Radiol · 2020-11-19

该回顾性单中心研究纳入183例极早期/早期肝细胞癌患者,按倾向性评分匹配后分为切除、射频消融和TACE三组(每组61例),分析钆塞酸增强MRI肝胆期特征与无病生存期和总生存期的关联。结果显示不同治疗组的预后相关因素不同,切除组大肿瘤尺寸与不良DFS和OS相关,RFA组卫星结节和瘤周低信号与不良预后相关,TACE组未发现与DFS/OS相关的变量。

要点

  • 切除组中,肝胆期大肿瘤尺寸与较差的无病生存期和总生存期相关。
  • RFA组中,肝胆期卫星结节和瘤周低信号与较差的无病生存期和/或总生存期相关。
  • TACE组中,未发现临床或肝胆期影像特征与无病生存期或总生存期相关。

关键影像表现/征象

  • 切除组中,肿瘤尺寸每增加1厘米与较差的无病生存期相关(HR 4.159;95%CI 1.669-10.365)。
  • 切除组中,肿瘤尺寸每增加1厘米与较差的总生存期相关(HR 8.498;95%CI 1.072-67.338)。
  • RFA组中,肝胆期图像上的卫星结节与较差的无病生存期相关(HR 5.037;95%CI 1.061-23.903)。
  • RFA组中,肝胆期图像上的卫星结节与较差的总生存期相关(HR 9.398;95%CI 1.480-59.668)。
  • RFA组中,肝胆期图像上的瘤周低信号与较差的总生存期相关(HR 13.062;95%CI 1.627-104.840)。

诊断标准与关键数值

  • 切除组:大肿瘤尺寸与较差的无病生存期相关(HR 4.159/厘米;95%CI 1.669-10.365)和较差的总生存期相关(HR 8.498/厘米;95%CI 1.072-67.338)。
  • RFA组:肝胆期卫星结节与较差的无病生存期相关(HR 5.037;95%CI 1.061-23.903)和较差的总生存期相关(HR 9.398;95%CI 1.480-59.668)。
  • RFA组:肝胆期瘤周低信号与较差的总生存期相关(HR 13.062;95%CI 1.627-104.840)。
  • RFA组:血清白蛋白水平和凝血酶原时间-国际标准化比值与无病生存期和/或总生存期相关(原文未报告具体数值)。
  • TACE组:未发现与无病生存期或总生存期相关的变量。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Patients with hepatocellular carcinoma (HCC) receiving different treatments might have specific prognostic factors that can be captured in the hepatobiliary phase (HBP) of gadoxetic acid-enhanced magnetic resonance imaging (GA-MRI). We aimed to identify the clinical findings and HBP features with prognostic value in patients with HCC.

METHODS: In this retrospective, single-institution study, we included patients with Barcelona Clinic Liver Cancer very early/early stage HCC who underwent GA-MRI before treatment. After performing propensity score matching, 183 patients received the following treatments: resection, radiofrequency ablation (RFA), and transarterial chemoembolization (TACE) (n = 61 for each). Cox regression models were used to identify clinical factors and HBP features associated with disease-free survival (DFS) and overall survival (OS).

RESULTS: In the resection group, large tumor size was associated with poor DFS (hazard ratio [HR] 4.159 per centimeter; 95% confidence interval [CI], 1.669-10.365) and poor OS (HR 8.498 per centimeter; 95% CI, 1.072-67.338). In the RFA group, satellite nodules on HBP images were associated with poor DFS (HR 5.037; 95% CI, 1.061-23.903) and poor OS (HR 9.398; 95% CI, 1.480-59.668). Peritumoral hypointensity on HBP images was also associated with poor OS (HR 13.062; 95% CI, 1.627-104.840). In addition, serum albumin levels and the prothrombin time-international normalized ratio were associated with DFS and/or OS. Finally, in the TACE group, no variables were associated with DFS/OS.

CONCLUSIONS: Different HBP features and clinical factors were associated with DFS/OS among patients with HCC receiving different treatments.

KEY POINTS: • In patients who underwent resection for HCC, a large tumor size on HBP images was associated with poor disease-free survival and overall survival. • In the RFA group, satellite nodules and peritumoral hypointensity on HBP images, along with decreased serum albumin levels and PT-INR, were associated with poor disease-free survival and/or overall survival. • In the TACE group, no clinical or HBP imaging features were associated with disease-free survival or overall survival.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Bae JS, Kim JH, Lee DH, et al. Hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with HCC: prognostic features before resection, ablation, or TACE. Eur Radiol. 2020. PMID: 33211146. doi:10.1007/s00330-020-07499-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。